Diallyl Trisulfide Suppresses Growth of PC-3 Human Prostate Cancer Xenograft In vivo in Association with Bax and Bak Induction

Dong Xiao, Karen L. Lew, Young-Ae Kim, Yan Zeng, Eun-Ryeong Hahm, Rajiv Dhir, and Shivendra V. Singh

Abstract

Purpose: The present study was undertaken to determine the effect of garlic constituent diallyl trisulfide (DATS) on growth of PC-3 human prostate cancer xenograft in vivo.

Experimental Design: DATS was given orally (6 μM, thrice weekly) to male athymic mice s.c. implanted with PC-3 cells. Tumor sections from control and DATS-treated mice were examined for apoptotic bodies by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling assay. Protein levels of apoptosis and cell cycle regulating proteins in tumor tissues of control and DATS-treated mice were determined by immunoblotting. The effect of DATS treatment on in vivo angiogenesis was determined by immunohistochemical analysis of CD31 in tumors.

Results: Oral gavage of DATS significantly retarded growth of PC-3 xenografts in athymic mice without causing weight loss. For instance, 20 days after starting therapy, the average tumor volume in control mice was ~3-fold higher compared with DATS-treated mice. Tumors from DATS-treated mice exhibited a markedly higher count of apoptotic bodies compared with control tumors. Consistent with the results in cultured PC-3 cells, the DATS-mediated suppression of PC-3 xenograft growth correlated with induction of proapoptotic proteins Bax and Bak. Although DATS treatment inhibited migration of cultured PC-3 cells in association with down-regulation of vascular endothelial growth factor receptor-2 protein, formation of new blood vessels was comparable in tumors of control and DATS-treated mice as judged by CD31 immunostaining.

Conclusions: The present study indicates that DATS administration inhibits growth of PC-3 xenografts in vivo in association with induction of Bax and Bak.

Epidemiologic studies continue to support the premise that dietary intake of Allium vegetables, such as garlic, may reduce the risk of various types of malignancies, including cancer of the prostate (1–4). For example, the risk of prostate cancer was significantly lower in men consuming >10 g/d of total Allium vegetables than in men with total Allium vegetable intake of <2.2 g/d in a population-based case-control study (4). Laboratory studies indicate that the anticarcinogenic effect of Allium vegetables is due to organosulfur compounds (OSC), which are generated on processing (e.g., cutting or chewing) of these vegetables (5). Garlic-derived OSCs, including diallyl sulfide, diallyl disulfide (DADS), and diallyl trisulfide (DATS) have been shown to afford significant protection against cancer in animal models induced by a variety of chemical carcinogens (6–11). For example, prevention of chemically induced cancer by naturally occurring OSC analogues has been observed against benzo[a]pyrene-induced forestomach and pulmonary carcinogenesis in mice (8). N-nitrosomethylbenzylamine-induced esophageal cancer in rats (9), and azoxymethane-induced colon carcinogenesis in rats (10). Induction of phase 2 carcinogen-detoxifying enzymes, such as glucathione transferases and quinone reductase, and inhibition of phase 1 carcinogen-activating enzymes are believed to be responsible for prevention of chemically induced cancers by OSCs (12–14). We have also shown previously that DADS administration significantly inhibits membrane association of oncogenic p21ras in vivo (15).

Recent studies have revealed that certain garlic-derived OSCs can suppress proliferation of cultured cancer cells by causing apoptosis and/or cell cycle arrest (16–27). Apoptosis induction and cell cycle arrest was first documented for DATS in human colon cancer cells (16, 17). The DADS-induced apoptosis in colon cancer cells correlated positively with an increase in intracellular free calcium level (16). The DADS-induced cell cycle arrest was accompanied by an increase in cyclin B1 protein level, a decrease in complex formation between cyclin B1 and cyclin-dependent kinase (CDK) 1, and hyperphosphorylation of CDK1 (17). We have shown recently that DATS is a much more potent suppressor of PC-3 human prostate cancer cell proliferation compared with either diallyl sulfide or DADS (22). We also found that the proliferation of a normal prostate epithelial cell line is minimally affected by DATS even at concentrations that are highly cytotoxic to the prostate cancer cells (22). The DATS-mediated inhibition of PC-3 cell proliferation is associated with G2 phase as well as mitotic

Authors’ Affiliation: Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Received 5/24/06; revised 8/14/06; accepted 8/28/06.

Grant support: National Cancer Institute, United States Public Health Service grant CA113363.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Shivendra V. Singh, Department of Pharmacology, 2.32A Hillman Cancer Center Research Pavilion, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-623-3263; Fax: 412-623-7828; E-mail: singhsv.upmc.edu.

© 2006 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-06-1273

Clin Cancer Res 2006;12(22) November 15, 2006 6836 www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 20, 2017. © 2006 American Association for Cancer Research.
arrest and apoptosis induction (22, 23, 25–27). The DATS-induced G2 phase cell cycle arrest is caused by reactive oxygen species–dependent destruction and hyperphosphorylation of Cdc25C (23), whereas activation of checkpoint kinase 1 regulates the mitotic arrest executed by DATS (25). The DATS-induced apoptosis in PC-3 cells is associated with activation of caspase-3 and partially attenuated by ectopic expression of Bcl-2 as well as overexpression of constitutively active Akt (22, 26).

Cultured cancer cells are valuable not only for rapid screening of potential anticancer agents but also for gaining mechanistic insights not accessible otherwise. However, the observations made in cultured cancer cells need to be confirmed using appropriate animal models to test in vivo significance of the cellular findings. Moreover, in vivo efficacy testing of potential anticancer agents is a prerequisite for their further development as clinically useful agents. The present study was designed to test whether DATS administration affects growth of PC-3 cells in vivo. We now show that oral administration of DATS significantly retards growth of PC-3 xenografts in athymic mice without causing weight loss or any other side effects. The present study also reveals that the DATS-mediated inhibition of PC-3 xenograft growth correlates with induction of multidomain proapoptotic proteins Bax and Bak.

**Materials and Methods**

**Reagents and cell culture.** DATS was procured from LKT Laboratories (St. Paul, MN). Tissue culture medium, fetal bovine serum, and antibiotics were from Life Technologies (Grand Island, NY). Antibodies against Bak, Bcl-xl, cyclin B1, and vascular endothelial growth factor receptor-2 (VEGFR-2) were from Santa Cruz Biotechnology (Santa Cruz, CA); antibodies against Bax, Bid, and Cdc25B were from Pharmingen (San Diego, CA); anti-Cdc25C antibody was from Cell Signaling (Beverly, MA); anti-Bcl-2 antibody was from DakoCytomation (Carpinteria, CA); antibody specific for detection of phosphorylated (Ser10) histone H3 was from Upstate (Lake Placid, NY); and the antibodies against CDK1 and actin were from Sigma (St. Louis, MO). Monolayer cultures of PC-3 cells were maintained in F-12K Nutrient Mixture (Kaighn’s modification) supplemented with 7% nonheat inactivated fetal bovine serum and antibiotics. **Xenograft assay.** Male athymic mice (6 weeks old) were purchased from Taconic (Germantown, NY) and housed in accordance with the Institutional Animal Care and Use Committee guidelines. The use of mice for studies described herein was approved by the Institutional Animal Care and Use Committee. Exponentially growing PC-3 cells were mixed in a 1:1 ratio with Matrigel (Becton Dickinson, Bedford, MA) and a 0.1 mL suspension containing 1 × 104 cells was injected s.c. on both left and right flank of each mouse. Mice were randomized into two groups of five mice per group with tumors implanted on both left and right flanks (n = 10). Power analysis indicated that a sample size of 10 (five animals per group with tumors implanted on both left and right flanks) would provide at least 80% power to detect a 50% reduction in tumor volume at P = 0.05. The experiment was terminated 20 days after tumor cell injection because PC-3 is a relatively fast-growing tumor. Experimental mice were treated by oral gavage with 6 μmol. DATS in 0.1 mL PBS (Monday, Wednesday, and Friday) beginning the day of tumor cell implantation. Control mice received an equal volume of the vehicle. Tumor size was measured as described by us previously (28, 29). Body weights of the control and DATS-treated mice were recorded throughout the experiment. Mice of each group were also monitored for other symptoms of side effects, including food and water withdrawal and impaired posture or movement. At the termination of the experiment, the tumor tissues from control and DATS-treated mice were harvested and used for immunohistochemistry or immunoblotting.

**Histologic analysis of apoptotic bodies.** The tumor tissues from control and DATS-treated mice were fixed in 10% neutral buffered formalin, dehydrated, embedded in paraffin, and sectioned at 4-μm thickness. Apoptosis in tumor sections of control and DATS-treated mice was assessed by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) assay using ApopTag Peroxidase In situ Apoptosis Detection kit (Chemicon International, Temecula, CA) according to the manufacturer’s recommendations. The tumor sections were also stained with H&E.

**Immunoblotting.** A portion of the tumor tissues harvested from control and DATS-treated mice at the termination of the experiment were stored at −80°C until used. A 10% (w/v) homogenate of tumor tissues from control and DATS-treated mice was prepared in PBS containing protease inhibitor (BD Biosciences, San Diego, CA) and phosphatase inhibitor cocktail (Sigma) at 4°C using a polytron. The homogenate was centrifuged at 21,000 × g for 15 minutes. The supernatant proteins were resolved by sodium dodecyl sulfate PAGE and transferred onto polyvinylidene fluoride membrane (28, 29). After blocking with 5% nonfat dry milk in TBS containing 0.05% Tween 20, the membrane was incubated with the desired primary antibody for 1 hour at room temperature or overnight at 4°C. The membrane was then treated with appropriate secondary antibody and the immunoreactive bands were visualized using enhanced chemiluminescence method. Each membrane was stripped and reprobed with anti-actin antibody to normalize for differences in protein loading. Change in protein level was determined by densitometric scanning of the immunoreactive bands and corrected for actin loading control.

**In vitro migration assay.** The effect of DATS treatment on in vitro migration (invasion) by PC-3 cells was determined using Transwell Boyden chamber (Corning, Acton, MA) containing a polycarbonate filter with a pore size of 8 μm as described by us previously (30). Briefly, 0.2 mL PC-3 cell suspension containing 4 × 105 cells in complete medium was mixed with 10 or 20 μmol/L DATS or DMSO (control) and the suspension was added to the upper compartment of the chamber. The lower compartment of the chamber contained 0.6 mL of complete medium containing the same concentrations of DATS or DMSO. Following incubation at 37°C for 24 hours, the nonmigrating cells from the upper face of the Transwell membrane were removed using a cotton swab. The membrane was washed with PBS and the migrated cells on the bottom face of the membrane were fixed with 90% ethanol and stained with eosin. Three randomly selected fields on each membrane were scored for migrated cells.

**Immunohistochemistry for CD31.** The effect of DATS administration on formation of new blood vessels in vivo in PC-3 tumor xenograft was assessed by immunohistochemical analysis of CD31. Tumor sections (4 μm) were fixed in acetone for 10 minutes at 4°C. After endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 15 minutes, the sections were treated with normal rabbit serum for 20 minutes. The sections were then incubated with the primary anti-CD31 goat polyvalent antibody (1:750 dilution; Santa Cruz Biotechnology) for 1 hour at room temperature and washed with TBS. Biotinylated anti-goat IgG was applied for 30 minutes at room temperature. Color was developed by 10 minutes of incubation with the 3,3′-diaminobenzidine (DakoCytomation).

**Results**

**DATS inhibits growth of PC-3 xenografts in athymic mice.** We have shown previously that DATS inhibits growth of cultured PC-3 cells, but not a normal prostate epithelial cell line, by causing cell cycle arrest and apoptosis induction (22, 23, 25). To test in vivo relevance of these cellular findings, we determined the effect of DATS administration by oral gavage (6 μmol, thrice weekly) on PC-3 xenograft growth in athymic
mice. The DATS concentration used in the present study was within the range (up to 20 μmol) used in chemically induced carcinogenesis models (8, 10). The average tumor volume in mice treated with 6 μmol. DATS was significantly lower compared with vehicle-treated control mice throughout the experimental protocol (Fig. 1A). For example, 20 days after starting therapy, the average tumor volume in control mice (565 ± 112 mm³) was ~3-fold higher compared with DATS-treated mice. Similarly, on day 15, the average tumor volume in 6 μmol. DATS-treated mice was lower by ~55% compared with control mice. The DATS-mediated retardation of PC-3 xenograft growth in vivo was also evident in a separate study (data not shown).

The body weights of the control and experimental groups of mice were recorded periodically to determine whether DATS administration caused weight loss. As can be seen in Fig. 1B, the average body weights of the control and DATS-treated mice did not differ significantly throughout the experimental protocol. Moreover, the DATS-treated mice appeared healthy and did not exhibit impaired movement and posture, indigestion, and areas of redness or swelling. These results indicated that DATS administration significantly inhibited PC-3 xenograft growth without causing any side effects to the mice.

**DATS administration increases apoptosis in tumors.** We have shown previously that DATS suppresses proliferation of PC-3 cells in culture by causing apoptosis induction (22). To test whether DATS-mediated inhibition of PC-3 xenograft growth in vivo was due to increased apoptosis, tumor tissues from control and DATS-treated mice were examined for histologic evidence of apoptosis. The apoptotic bodies in tumor sections of control and DATS-treated mice were visualized by TUNEL staining and representative micrographs are shown in Fig. 2A. The tumors from DATS-treated mice exhibited a markedly higher count of brown-color apoptotic bodies compared with control tumors. The tumor sections from control and DATS-treated mice were also stained with H&E, and the results are shown in Fig. 2B. Eosin is an acidic stain, which interacts with cellular proteins rich in basic amino acids and commonly used for cytoplasmic staining. The eosin-protein complex is characterized by a vivid pink cytoplasmic staining. Hematoxylin is a nuclear stain that interacts with negatively charged phosphate groups of nuclear DNA forming a blue-purple color. The staining for hematoxylin was relatively brighter in tumors of DATS-treated mice compared with control mice (Fig. 2B). We have shown previously that DATS treatment causes mitotic arrest in cultured PC-3 cells that is characterized by chromatin condensation and Ser10 phosphorylation of histone H3 (25). The Ser10 phosphorylation of histone H3 has emerged as a sensitive marker for mitotic cells (31). We therefore determined the level of phosphorylated (Ser10) histone H3 using tumor supernatants from control and DATS-treated mice by immunoblotting to test whether DATS treatment resulted in mitotic arrest in vivo. The level of Ser10-phosphorylated histone H3 was comparable in tumors of control and DATS-treated mice (data not shown). These results indicated that the DATS-mediated suppression of PC-3 xenograft growth in vivo was associated with increased apoptosis.

**DATS administration increases protein levels of Bax and Bak in tumors.** The Bcl-2 family proteins have emerged as critical regulators of apoptosis by functioning as either inhibitors (Bcl-2 and Bcl-xL) or promoters (Bax, Bak, and Bid) of the cell death process (32–34). To gain insights into the mechanism of DATS-mediated suppression of PC-3 xenograft growth, we compared the levels of Bcl-2 family proteins in tumors from control and DATS-treated mice. Representative immunoblots for Bax, Bak, Bcl-xL, Bid, and Bcl-2 proteins using tumor supernatants from control and DATS-treated mice are shown in Fig. 3A. Change in protein level was quantified by densitometric scanning of the immunoreactive bands and corrected for actin loading control. As can be seen Fig. 3B, the protein levels of Bax and Bak were statistically significantly higher in tumors from DATS-treated mice compared with control tumors. For instance, the protein level of Bax was ~2.1-fold higher in tumors of DATS-treated mice compared with control tumors (Fig. 3B). Similarly, the tumors from DATS-treated mice exhibited an ~3.7-fold increase in Bak protein level compared with control tumors. The tumors from DATS-treated mice also exhibited an increasing trend in the protein level of Bcl-xL and a decreasing trend in the level of Bid protein compared with control tumors, although the differences did not reach statistical significance ($P > 0.05$, paired $t$ test). The protein level of Bcl-2 was comparable in tumors of control and

![Fig. 1. A. average tumor volume in vehicle-treated control mice and mice treated with 6 μmol DATS (Monday, Wednesday, and Friday). The DATS administration was started on the day of tumor cell injection. Points, mean (n = 10; five mice per group with tumors cells injected on both left and right flank of each mouse); bars, SE. *<P < 0.05, significantly different compared with control by two-way ANOVA. B. average body weights of control and 6 μmol DATS-treated mice. The body weights of the control and DATS-treated mice did not differ significantly throughout the experimental protocol. Points, mean (n = 5); bars, SE.](http://www.aacrjournals.org/clincri/2006/122115/6838)
DATS-treated mice. These results indicated that DATS-mediated suppression of PC-3 xenograft growth in vivo was accompanied by induction of multidomain proapoptotic proteins Bax and Bak.

We have shown previously that the DATS-induced G2-M phase cell cycle arrest in PC-3 cells is associated with a reduction in protein levels of CDK1 and Cdc25C and an increase in cyclin B1 protein level (23, 25). These proteins play an important role in regulation of G2-M transition (35). We therefore compared the levels of CDK1, cyclin B1, Cdc25B, and Cdc25C proteins by immunoblotting using tumor supernatants from control and DATS-treated mice (Fig. 4A) to test in vivo relevance of the cellular findings. The levels of the above cell cycle regulatory proteins did not differ significantly between tumors of control and DATS-treated mice (Fig. 4B). These

![Figure 2](image-url)

**Fig. 2.** A, TUNEL staining for apoptotic bodies in tumor sections from control and DATS-treated mice. Representative TUNEL staining in tumor sections from two different control and DATS-treated mice is shown. The tumors from DATS-treated mice exhibited a markedly higher count of brown-color apoptotic bodies compared with control tumors. B, histologic analysis of tumors from control and DATS-treated mice by H&E staining. Representative H&E staining in tumor sections from two different control and DATS-treated mice is shown.

![Figure 3](image-url)

**Fig. 3.** A, immunoblotting for Bcl-2 family proteins using tumor supernatants from control and DATS-treated mice. The blots were stripped and reprobed with anti-actin antibody to correct for differences in protein loading. B, densitometric scanning data for Bcl-2 family protein levels in tumors from control and DATS-treated mice. Tumor tissues from four or five mice of each group were used for immunoblotting. Columns, mean (n = 4–5); bars, SE. *, P < 0.05, significantly different compared with control by paired t test.
immunoblotting using lysates from PC-3 cells treated with an important role in angiogenesis (36), as revealed by ical vein endothelial cells (30), DATS treatment caused a respectively, compared with control. Similar to human umbilical vein endothelial cells (30), DATS treatment significantly inhibits growth of androgen-independent PC-3 xenografts in athymic mice without causing weight loss or any other side effects. We also found that the DATS-mediated inhibition of PC-3 xenograft growth in vivo is associated with an increase in apoptotic bodies. These observations are consistent with cellular studies where treatment of PC-3 cells with DATS results in a concentration-dependent apoptosis induction (22). Thus, it is reasonable to conclude that apoptosis induction is a critical event in DATS-mediated suppression of PC-3 cell growth in vivo.

Cellular systems are valuable in obtaining mechanistic insights not accessible otherwise. The observations made in cells, however, need to be confirmed in animal models to establish in vivo relevance of the cellular findings. In addition, identification of an appropriate biomarker(s) of in vivo response can be an equally important consideration in clinical development of potential chemopreventive and therapeutic agents. Identification of biomarker(s) is especially desirable for cancer chemoprevention trials because reduction of cancer incidence is too rigorous endpoint for malignancies with a

Discussion

According to the American Cancer Society, prostate cancer is the most commonly diagnosed malignancy in American men after skin cancer. The society estimates diagnosis of ~234,460 new cases of prostate cancer in the United States in 2006. About 27,350 men are expected to die of this disease in the year 2006. Prostate cancer is the third leading cause of cancer-related deaths in men, after lung cancer and colorectal cancer. Molecular mechanism underlying onset or progression of prostate cancer is not fully defined, but age, race, diet, and androgen secretion and metabolism are the identifiable risk factors associated with this malignancy (37, 38). Therapeutic options exist for localized disease, including surgery, radiation therapy, and hormonal therapy. Androgen ablation is a frequently prescribed treatment option for prostate cancer (39). This treatment modality, however, is palliative and has limited scope for hormone-refractory prostate cancers (39). Moreover, chemotherapy and radiation therapy are largely ineffective against advanced prostate cancer (40, 41). Prostate cancer is usually diagnosed in the 6th and 7th decades of life, which allows a large window of opportunity for intervention to prevent or slow progression of the disease. Therefore, clinical development of agents that are nontoxic to normal cells but can delay onset and/or progression of human prostate cancer, especially hormone-independent prostate cancers, could have a significant effect on disease-related cost, morbidity, and mortality for a large segment of population. The present study provides experimental evidence to indicate that DATS, which is a naturally occurring constituent of processed garlic, significantly inhibits growth of androgen-independent PC-3 xenografts in athymic mice without causing weight loss or any other side effects. We also found that the DATS-mediated inhibition of PC-3 xenograft growth in vivo is associated with an increase in apoptotic bodies. These observations are consistent with cellular studies where treatment of PC-3 cells with DATS results in a concentration-dependent apoptosis induction (22). Thus, it is reasonable to conclude that apoptosis induction is a critical event in DATS-mediated suppression of PC-3 cell growth in vivo.

Cellular systems are valuable in obtaining mechanistic insights not accessible otherwise. The observations made in cells, however, need to be confirmed in animal models to establish in vivo relevance of the cellular findings. In addition, identification of an appropriate biomarker(s) of in vivo response is an equally important consideration in clinical development of potential chemopreventive and therapeutic agents. Identification of biomarker(s) is especially desirable for cancer chemoprevention trials because reduction of cancer incidence is too rigorous endpoint for malignancies with a
long latency, such as prostate cancer. The present study reveals that the DATS-mediated suppression of PC-3 xenograft growth in vivo is accompanied by induction of Bak and Bax, which function to promote cell death by neutralizing antiapoptotic effects of Bcl-2 and Bcl-xL (42, 43). Mouse embryonic fibroblasts (MEF) derived from Bax and Bak double knockout mice are significantly more resistant to apoptosis induction by different agents, including dietary cancer chemopreventive agents sulforaphane and phenethyl isothiocyanate compared with wild-type MEFs (44–46). Recent unpublished studies from our laboratory have revealed that DATS treatment causes apoptotic cell death in association with an increase in the protein levels of Bax and Bak in SV40-immortalized MEFs derived from wild-type mice, but the immortalized MEFs derived from Bax and Bak double knockout mice are significantly more resistant to DATS-induced cell death compared with wild-type MEFs. These results suggest that Bak and Bak may serve as useful biomarkers of DATS efficacy, but validation of this hypothesis awaits clinical trials.

Eukaryotic cell cycle progression is regulated by sequential activation of CDKs whose association with regulatory cyclins is essential for their activation (35). A complex between CDK1 and cyclin B1 plays an important role in regulation of G2-M transition (35). The CDK1/cyclin B1 complex is retained in an inactive state by reversible phosphorylations at Thr14 and Tyr15.

---

![Fig. 5.](image-url)

A, representative images depicting effect of DATS treatment (24 hours) on PC-3 migration as determined by Boyden chamber assay. The migration by PC-3 cells was inhibited significantly in the presence of DATS in a concentration-dependent manner. Columns, mean (n = 3); bars, SE (d). *P < 0.05, significantly different compared with DMSO-treated control by one-way ANOVA followed by Dunnett's test.

B, immunoblotting for VEGFR-2 using lysates from PC-3 cells treated with 20 μmol/L DATS for the indicated times. The blot was stripped and reprobed with anti-actin antibody to ensure equal protein loading. C, immunohistochemical analysis of CD31 using tumor sections from control and DATS-treated mice. The CD31 staining was comparable in tumor sections from control and 6 μmol DATS-treated mice, indicating lack of an inhibitory effect of DATS treatment on formation of blood vessels.

---

Mum to detect DATS-mediated tumor tissue collection at the time of animals sacrifice is not optimal. It is also possible that the timing of levels of cell cycle regulatory proteins in tumors in a time course analysis of effect of DATS administration on cycleregulatory proteins. Carefully designed experiments, including a time course effect of DATS administration on levels of cell cycle regulatory proteins in tumors in vivo, are needed to systematically explore these possibilities.

We have shown previously that DATS is a potent inhibitor of in vitro capillary-like tube formation and migration by human umbilical vein endothelial cells (30). The DATS-mediated inhibition of migration of human umbilical vein endothelial cells is associated with inactivation of Akt, suppression of VEGF secretion, and down-regulation of VEGFR-2 protein (30). Consistent with these results, DATS treatment causes inhibition of migration by PC-3 cells, which is accompanied by a decrease in protein level of VEGFR-2 (Fig. 5). Despite these effects in cultured PC-3 cells, DATS administration does not inhibit angiogenesis in PC-3 xenograft in vivo as judged by immunohistochemical analysis of CD31.

The DATS-mediated growth arrest and apoptosis induction in prostate cancer cells, including PC-3 cell line, is observed at concentrations (10-40 μmol/L) pharmacologically achievable based on a recent pharmacokinetic study (47). The concentration of DATS in rat blood following treatment with 10 mg DATS is ~34 μmol/L (47). Although the pharmacokinetic variables for DATS in humans have not yet been measured, oral administration of 200 mg of synthetic DATS (also known as allitridum) in combination with 100 μg selenium every other day for 1 month to humans did not cause any harmful side effects (48). It is therefore possible that the plasma concentrations of DATS required for cancer cell growth inhibition may be achievable in humans.

In conclusion, the present study indicates that (a) the DATS administration significantly retards growth of PC-3 xenografts in athymic mice without causing weight loss or any other side effects and (b) the DATS-mediated suppression of PC-3 xenograft growth in vivo correlates with induction of Bak and Bak proteins. We are tempted to speculate that Bak and Bak may serve as useful biomarkers of DATS response in vivo.


Diallyl Trisulfide Suppresses Growth of PC-3 Human Prostate Cancer Xenograft *In vivo* in Association with Bax and Bak Induction

Dong Xiao, Karen L. Lew, Young-Ae Kim, et al.


Updated version  Access the most recent version of this article at: [http://clincancerres.aacrjournals.org/content/12/22/6836](http://clincancerres.aacrjournals.org/content/12/22/6836)

Cited articles  This article cites 47 articles, 24 of which you can access for free at: [http://clincancerres.aacrjournals.org/content/12/22/6836.full.html#ref-list-1](http://clincancerres.aacrjournals.org/content/12/22/6836.full.html#ref-list-1)

Citing articles  This article has been cited by 14 HighWire-hosted articles. Access the articles at: [http://clincancerres.aacrjournals.org/content/12/22/6836.full.html#related-urls](http://clincancerres.aacrjournals.org/content/12/22/6836.full.html#related-urls)

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.